Sylvie Lorenzen

机构：TUM Klinikum, Technical University of Munich · ORCID：0000-0001-7933-2507

发表论文 294 篇 · 总被引 6461 次 · h-index 39

代表论文

• Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study (2024 · Annals of Oncology · 被引 61)
• Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial (2025 · Nature Medicine · 被引 23)
• Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of esophageal adenocarcinoma (2025 · Nature Cancer · 被引 16)
• EORTC-1203 GITC "INNOVATION": Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy of HER-2 positive stomach cancer: Overall survival results. (2025 · Journal of Clinical Oncology · 被引 15)
• Conversion Therapy for Stage IV Gastric Cancer: Report From the Expert Consensus Meeting at KINGCA WEEK 2024 (2025 · Journal of the Korean Gastric Cancer Association · 被引 10)
• Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy (2024 · Cancer Immunology Research · 被引 7)